Overview
Thymosin alpha-1 was isolated from the thymus and is produced synthetically as thymalfasin. It is approved in several countries in Asia, Europe and Latin America for indications such as chronic hepatitis B and as an immune adjuvant. It remains under research in oncology and infectious disease.
Mechanism of action
Acts on Toll-like receptors (TLRs) in dendritic cells, promoting T-cell maturation and Th1-type immune responses.
Research areas
- Immunology
- Viral hepatitis
- Immuno-oncology
Selected references
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016;102:151–178. PubMed ↗